Industry News

Aetna-Humana Transaction--. HARTFORD, Conn.& LOUISVILLE, Ky.---- Aetna and Humana Inc. today announced they have entered into separate agreements to sell certain of their respective Medicare Advantage assets to Molina Healthcare, Inc. for a total estimated $117 million in cash for both..."/>
Aetna and Humana Agree to Sell Certain Medicare Advantage Assets to Molina Healthcare, Inc.
Aetna-Humana Transaction. HARTFORD, Conn.& LOUISVILLE, Ky.---- Aetna and Humana Inc. today announced they have entered into separate agreements to sell certain of their respective Medicare Advantage assets to Molina Healthcare, Inc. for a total estimated $117 million in cash for both..."/>
Aetna and Humana Agree to Sell Certain Medicare Advantage Assets to Molina Healthcare, Inc.
Orexigen Therapeutics said on Monday that its wholly owned subsidiary Orexigen Therapeutics Ireland Ltd has announced a commercialisation and distributorship agreement for Mysimba in Spain in partnership with Laboratorios Farmaceuticos Rovi SA. Mysimba is reportedly approved by the European Medicines Agency for the management of weight in adult patients with an initial Body Mass Index of>= 30 kg/m2, or>= 27 kg/m2 to. As part of the agreement, ROVI..."/>
Orexigen Therapeutics signs commercialisation and distributorship agreement for Mysimba in Spain with Laboratorios Farmace?uticos Rovi
Aetna projects full-year 2016 net income per share of $6.28 to $6.48 Aetna reaffirms full-year 2016 operating earnings per share projection of $7.90 to $8.10. HARTFORD, Conn.---- Aetna announced second quarter 2016..."/>
Aetna Reports Second-Quarter 2016 Results
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced positive top-line results from a recently completed Phase 1 b multiple ascending dose clinical safety study of CMX157, ContraVir's novel, highly potent lipid conjugate of tenofovir in development for treating hepatitis B infection. Data from the Phase 1 b study demonstrate that..."/>
ContraVir Reports Positive Data from Phase 1b Study of CMX157
Mallinckrodt plc, a leading global specialty pharmaceutical company, today reported results for the third quarter of fiscal 2016 1. Unless otherwise noted, all comparisons of fiscal 2016 third quarter or year-to-date performance are to the comparable periods of fiscal 2015.. Total Mallinckrodt net sales were $970.6 million in the third quarter of fiscal 2016, up 10.6%, or 10.8% on a constant-currency basis."/>
Mallinckrodt plc Reports Fiscal 2016 Third Quarter Results and Provides Guidance for Calendar Year 2016
Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today announced that data for its proprietary technology was published in the Herald Scholarly Open Access Journal of Stem Cells Research, Development and Therapy, which is available online at http://ow.ly/ZFzM300Yt1m.. Results from the Indian study titled,“ Enhancement of Atrophic Non-Union Fracture Healing Using Autologous Progenitor Cell-Rich Bone..."/>
Cesca Therapeutics Announces Publication of Results on Use of Its Technology for Treatment of Non-Union Fracture
Orexigen Therapeutics said on Monday that it has closed the acquisition of the US rights to anti-obesity drug Contrave two months ahead of schedule. In conjunction with the purchase, the company has relaunched Contrave under its own sales organisation. Under the terms of the agreement, Orexigen is entitled to 100% of net sales and controls all US commercial and development activities."/>
Orexigen buys all US rights to anti-obesity drug Contrave and introduces US sales organisation
Agilent Technologies Inc announced on Monday that it has concluded the asset acquisition of iLab Solutions LLC, a provider of cloud-based solutions for core laboratory management. Financial details of this acquisition were not available. Agilent had announced its intent on 27 June 2016 to acquire substantially all of the assets of iLab, including iLab's technology, intellectual property and product portfolio, as well as employee talent."/>
Agilent Technologies announces completion of asset acquisition of iLab Solutions
Collegium Pharmaceutical announced on Monday that it has received a grant letter from the European Patent Office for a European Patent Application for Xtampza extended-release capsules. This application, which has been assigned the patent number 05759527.4, is part of the company's expanding patent portfolio covering Xtampza ER and the DETERx technology platform. The company added Xtampza ER is its first product utilising the DETERx technology..."/>
Collegium awarded European patent allowance for Xtampza ER for the management of pain
PDL BioPharma stated on Monday that it has paid the second tranche of USD50m to ARIAD Pharmaceuticals in exchange for the net revenues of Iclusig pursuant to the ARIAD Royalty Agreement. This second tranche to ARIAD Pharmaceuticals was due on the first anniversary of the closing date under the ARIAD Royalty Agreement for its Iclusig. Following the second tranche payment, PDL's royalty percentage will increase to 5.0% of the US and European..."/>
PDL BioPharma announces second tranche payment of USD50m to ARIAD Pharmaceuticals
Mylan NV reported on Monday the availability of Dextroamphetamine Sulfate Extended-release Capsules, 5 mg, 10 mg and 15 mg in the US market. The company said Dextroamphetamine Sulfate Extended-release Capsules, 5 mg, 10 mg, and 15 mg is the generic version of Amedra Pharmaceuticals LLC's Dexedrine. According to the company, it has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for..."/>
Mylan unveils generic Dexedrine Capsules in the US narcolepsy market
Bio-Techne Corporation revealed on Monday the completion of its acquisition of Advanced Cell Diagnostics of Newark, CA. This is Bio-Techne Corporation's ninth acquisition in the last three years. Financial terms of the agreement were not disclosed."/>
Bio-Techne Corporation concludes acquisition of Advanced Cell Diagnostics for undisclosed amount
Ceres via a merger agreement pursuant to Section 251 of the Delaware General Corporation Law, with Ceres surviving the merger as a wholly owned subsidiary of Land O'Lakes. Roman Merger Sub Inc, a wholly owned subsidiary of Land O'Lakes, commenced a tender offer for all the outstanding shares of Ceres common stock at a price of USD0.40 per share, net to the seller in cash, without interest thereon and..."/>
Land O’Lakes buys Ceres at a price of USD0.40 per share
EyeGate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced positive data from its Phase 1 b/2a trial assessing its lead product candidate, iontophoretic EGP-437, in the treatment of post-operative ocular inflammation and pain in cataract surgery patients. This portion of the trial enrolled 40 subjects that had previously..."/>
EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients
Cancer Genetics, Inc., a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will report financial results for the second quarter on Wednesday, August 10, 2016. The company and key management team members will also hold a live investor conference call and webcast at 8:30 AM Eastern on Wednesday, August 10 2016 to discuss the financial results and company updates. Wednesday, August 10, 8:30 AM..."/>
Cancer Genetics to Report Second Quarter Earnings on Wednesday, August 10
Mazor Robotics Ltd., a pioneer and a leader in the field of surgical guidance systems, generated revenue of $8.3 million for the second quarter ended June 30, 2016."/>
Mazor Robotics Reports Second Quarter Financial Results
Hutchison China Meditech Limited. Hutchison China MediTech Limited Reports Interim Results for the Six Months Ended June 30, 2016, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs. Group revenue up 27% to $104.5 million and net income attributable to Chi-Med of $0.5 million, reflecting a sharp increase in clinical investment. Innovation Platform- Seven drug candidates in 25 clinical trials including four..."/>
Chi-Med 2016 Interim Results
Hutchison China Meditech Limited. London: Tuesday, August 2, 2016: Hutchison China MediTech Limited today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who has tendered his resignation to spend more time on his existing responsibilities within the CK Hutchison Holdings Group. Dr Eldar, aged 63, has more than 35 years of experience as a senior executive, leading..."/>
Hutchison China Meditech Limited: Change of Non-Executive Directors
Hutchison China MediTech Limited today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who has tendered his resignation to spend more time on his existing responsibilities within the CK Hutchison Holdings Group. Dr Eldar, aged 63, has more than 35 years of experience as a senior executive, leading global operations in telecommunications, water, biotech and healthcare."/>
Hutchison China MediTech Limited (“Chi-Med”): Change of Non-executive Directors
Agilent Technologies Inc. today announced it has completed the asset acquisition of iLab Solutions LLC, a leader in cloud-based solutions for core laboratory management. Agilent announced its intent on June 27 to acquire substantially all of the assets of iLab, including iLab's technology, intellectual property and product portfolio, as well as employee talent. iLab Solutions' offerings enable Agilent's customers to easily and accurately book time in..."/>
Agilent Technologies Completes Asset Acquisition of iLab Solutions, a Leader in Cloud-Based Laboratory Management Software
BTG plc, a global specialist healthcare company, today announced that it has obtained European Conformity Mark from the Notified Body British Standards Institution following completion of the reclassification of DC Bead ® and DC Bead M1 TM as Class III medical devices under Rule 8 of Annex IX to Directive 93/ 42/ EEC. The assessment takes account of the characteristics of DC Bead ® and DC Bead M1 TM with regards to their ability to administer..."/>
BTG Announces Successful CE Mark Reclassification for DC Bead® to Class III Based on its Ability to Administer Medicines

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary694 Articles
Information Technology661 Articles
Financials551 Articles
Health Care400 Articles
Industrials385 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.